Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.41 |
| ▸ | QPCT | Q16769 | 2/20 | 0.41 |
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26438713 | 0.85 | TLR9 (0.48) | HRH3SUV39H2QPCTHRH4 | |
| SCHEMBL13407684 | 0.85 | HRH3 (0.45) | HRH3F10AOC3SUV39H2 | |
| SCHEMBL31696699 | 0.85 | MEN1 (0.51) | HRH3F10AOC3SUV39H2HRH4 | |
| SCHEMBL26437646 | 0.82 | HRH3 (0.54) | HRH3F10AOC3SUV39H2QPCT | |
| SCHEMBL26438459 | 0.81 | HRH3 (0.65) | HRH3F10AOC3SUV39H2QPCT | |
| SCHEMBL12758907 | 0.79 | HRH3 (0.41) | HRH3F10AOC3QPCTPIK3C3 | |
| SCHEMBL26437884 | 0.79 | SUV39H2 (0.47) | HRH3F10AOC3SUV39H2 | |
| SCHEMBL26437555 | 0.78 | HRH3 (0.45) | HRH3F10AOC3SUV39H2QPCT | |
| SCHEMBL26438620 | 0.78 | AOC3 (0.42) | HRH3F10AOC3SUV39H2QPCT | |
| SCHEMBL26437436 | 0.77 | HRH3 (0.49) | HRH3F10AOC3SUV39H2QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076354-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HRH3 1041/4885CHKA 870/4885F10 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.